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The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent
endometrial carcinoma. Chemotherapy-naı ¨ve or previously treated patients (one regimen) with histopathologically documented
endometrial carcinoma and Eastern Cooperative Oncology Group performance status p2 entered the study. Docetaxel 70mgm
 2
was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel,
additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of
59 years (range, 39–74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32
patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1–50.0%); complete
response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median
duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3–4
neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild
and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those
previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most
patients.
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Most patients with endometrial cancer are diagnosed at an early
stage when surgery alone may result in cure. However, the
outcome for women with advanced stage or recurrent disease is
poor and rarely curable. Both single-agent and combination
regimens of chemotherapy have been studied in women with
advanced endometrial carcinoma. Currently, no standard chemo-
therapy regimen for endometrial cancer exists, but single-agent
doxorubicin is active, with responses observed in up to one-third
of previously untreated patients (Moore et al, 1991). Other single
agents with modest activity include cisplatin (Thigpen et al, 1984a,
1989) and carboplatin (van Wijk et al, 2003). Although the
response rates with the combination doxorubicin cisplatin appear
to be higher than those achieved with either agent alone, there is
no evidence that survival is any longer with combination therapy.
In the Gynecologic Oncology Group (GOG) trial comparing
doxorubicin alone with doxorubicin cisplatin, the response rates
and progression-free survival were better with the combination
regimen (42 vs 25%, 5.7 vs 3.8 months, respectively), but overall
survival (OS) had not significantly improved (Thigpen et al, 2004).
The taxanes, paclitaxel and docetaxel, are potent chemother-
apeutic agents that block tubulin depolymerisation, leading to the
inhibition of microtubule dynamics, and have significant clinical
efficacy for various solid tumours. Paclitaxel has been evaluated as
an active agent for endometrial cancer (Ball et al, 1996; Lissoni
et al, 1996; Lincoln et al, 2003). However, preclinical data show
that docetaxel has increased potency and an improved therapeutic
index compared with paclitaxel (Bissery et al, 1995), and its short
1-h infusion time offers a substantial clinical advantage over the
prolonged infusion durations required with paclitaxel. Docetaxel
and paclitaxel also have substantially different toxicity profiles. In
particular, docetaxel has a significant lower incidence of neuro-
toxicity in comparison to paclitaxel (Hsu et al, 2004).
The present phase II trial was designed to evaluate the clinical
efficacy and tolerability of docetaxel 70mgm
 2 in patients with
advanced or recurrent endometrial cancer.
PATIENTS AND METHODS
Eligibility criteria
Eligible patients aged between 20 and 74 years, with a life
expectancy in excess of 3 months, and Eastern Cooperative
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sOncology Group (ECOG) Performance Status (PS) of 0 2 had
histologically documented primary stage III, IV or recurrent
endometrial carcinoma. Tumours were staged according to the
International Federation of Gynecology and Obstetrics criteria.
All patients had measurable disease according to the response
evaluation criteria in solid tumours (RECIST) (Therasse et al,
2000). Measurable lesions defined unidimensionally were X20mm
using conventional imaging, or X10mm with spiral computed
tomographic scan. Patients were either chemotherapy-naive or had
received one prior chemotherapy regimen for endometrial cancer,
with 4 weeks between prior therapy and study treatment. Prior
treatment with a taxane was not allowed. Adequate organ function
was required for study entry: neutrophil count X2000ml
 1, platelet
count X100000ml
 1, haemoglobin X9.0gdl
 1, serum bilirubin
level p1.5mgdl
 1, normal hepatic function (asparate amino-
transferase (AST), alanine aminotransferase (ALT) and alkaline
phosphatase (ALP) levels p2.5 times upper limit of the institu-
tional normal (ULN)), serum creatinine level p1.5mgdl
 1, PaO2
X60mmHg and normal electrocardiogram. Patients with any of
the following conditions were excluded from the study: sarcoma
component, active infection, severe heart disease, interstitial
pneumonitis, past history of hypersensitivity, peripheral neuro-
pathy, malignant or benign effusions requiring drainage, active
brain metastasis, or active concomitant malignancy. All patients
gave informed consent before entering this study, which was
approved by the institutional review boards at all participating
institutions.
Treatment schedule
Docetaxel 70mgm
 2 was infused over a 1–2-h period. The
treatment was repeated every 3 weeks unless there was documen-
ted disease progression or unacceptable toxicity. Prophylactic
medications for nausea, vomiting or hypersensitivity reactions
were given if these symptoms occurred. No routine premedication
was given for hypersensitivity reactions and fluid retention during
the first cycle of treatment. The patient’s physician identified all
hypersensitivity reactions and, if deemed necessary, the investi-
gator administered premedication drugs.
Treatment was delayed for up to 3 weeks in the event of toxicity,
but was restarted when the neutrophil count was X1500ml
 1,
platelet count X100000ml
 1, AST/ALT/ALP levels p2.5 times
ULN, and neuropathy or oedema pgrade 1. Docetaxel dosage was
reduced by 10mgm
 2 if febrile neutropenia occurred, if there was
bleeding with grade 3 4 thrombocytopenia requiring a platelet
transfusion, or if a patient experienced any grade 3 4 non-
haematologic toxicities except nausea, vomiting, anorexia, fatigue,
alopecia or hypersensitivity.
Response and toxicity evaluation
The tumour response was assessed according to the standard
RECIST criteria (Therasse et al, 2000). Target lesions included
all measurable lesions up to a maximum of five lesions per organ
and 10 lesions in total. Complete response (CR) was defined as the
complete disappearance of all target and nontarget lesions, with no
development of new disease. Partial response (PR) was defined as a
reduction by X30% in the sum of the longest diameter of target
lesions. Complete response or PRss were confirmed by repeat
assessments performed no less than 4 weeks after the criteria for
response were first met. Progressive disease (PD) was defined as an
increase by X20% in the sum of the longest diameter of all target
lesions, or the appearance of one or more new lesions and/or
unequivocal progression of existing, nontarget lesions. Stable
disease (SD) was defined as neither sufficient lesion shrinkage
to qualify for a PR, nor sufficient increase to qualify for PD. Best
response was defined as the most CR achieved by a patient (thus,
each patient had a single best response: CR, PR, SD or PD), and the
date of best response was the date it was first detected. Time to
progression (TTP) was defined as the time from the first
medication to the date of a PD event or death (due to endometrial
cancer or study drugs). All tumours were radiographically assessed
for response every 6 weeks. An independent response review
committee (IRRC) evaluated all tumour responses after the
investigators had completed their judgement.
Toxicities were evaluated with respect to incidence and severity
using National Cancer Institute common toxicity criteria (NCI-
CTC, version 2.0) (Trotti et al, 2000).
Statistical consideration
Assuming a response rate of 20%, the study was designed with 80%
power such that the lower limit of the 95% confidence interval (CI)
for the estimate of the response rate was greater than 0.05. A
sample size of 32 evaluable patients was required.
The primary end point was overall tumour response (deter-
mined by the IRRC) with the corresponding 95% CI using the exact
binominal method for the evaluable population. The secondary
end point of this study was safety. The Kaplan–Meier (KM)
method was used to determine the TTP and median survival time
(MST) in the evaluable population.
RESULTS
Patient characteristics
A total of 33 patients were enrolled on the study from April 2001 to
October 2003 and one patient was unevaluable as a result of having
received prior treatment with paclitaxel and doxorubicin plati-
num regimens. The median age of the intent to treat (ITT)
population (n¼33) was 59 years (range 39–74) and 70% patients
had ECOG PS 0 (Table 1). Several patients had unfavourable
histologic characteristics: adenosquamous features (three) and
uterine papillary serous cancers (two). Most patients (88%) had
undergone total abdominal hysterectomy and bilateral salpingo-
oophorectomy, and one-third of patients had prior radiotherapy.
Of those patients who had received prior chemotherapy (n¼14),
10 had received combination doxorubicin platinum in combina-
tion, three had received platinum alone and one had received oral
fluorouracil. All 33 patients were evaluated for toxicity and
survival, while 32 patients were evaluated for response and TTP.
Treatment delivery
Overall, 32 patients received a total of 133 cycles of docetaxel and
the median number of cycles of docetaxel was four (range, 1 13).
Five patients (15%) experienced dose reductions for the following
reasons: two patients experienced febrile neutropenia (in one
patient this occurred twice) and three patients had grade 3
nonhaematologic toxicities: diarrhoea (occurred twice in one
patient), hyperglycaemia, hyperkalaemia and supraventricular
tachycardia.
Response
Table 2 presents the assessment of response to treatment. Two
patients, one who was chemotherapy-naı ¨ve and the other who had
received prior therapy, were not assessable for response because
they had received only one cycle of treatment. Before evaluation by
the IRRC, primary physicians had reported two CRs and nine PRs.
The IRRC judged one CR as a PR, two PR as SD and one SD as
a PR. Therefore, the overall response rate for 10 of 32 patients
was 31% (95% CI, 16.1–50.0%). Of 13 patients who had prior
chemotherapy, three (23%) achieved a PR: two had received
doxorubicin platinum and one platinum alone. The histologic
analysis revealed responses among the following tumour types:
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sendometrioid adenocarcinoma (6 of 25 patients), squamous
differentiated adenocarcinoma (1 of 3), papillary serous (2 of 2)
and undifferentiated cancer (1 of 1). The median time for the onset
of effect was 2.0 months (range, 0.7–4.5) and the median duration
of response was 1.8 months (range, 0.9 4.6). The median follow-
up time was 17.6 months (range, 1.7 36.3) and median TTP was
3.9 months (95% CI, 1.5 10.2 months) (Figure 1). Median survival
time was 17.8 months (95% CI, 7.4 22.0 months).
Safety and toxicity
In all, 33 patients were assessable for toxicity (Table 3). Also, 31
(94%) patients experienced grade 3 or 4 neutropenia, and three
(9%) developed febrile neutropenia. Nonhaematologic toxicities
included grade 3 anorexia and vomiting experienced by some
patients (18 and 9%, respectively). One patient experienced grade 3
peripheral neuropathy (sensory and motor) after five treatment
cycles. Three patients terminated the study as a consequence of the
following toxicities: infection with Mycobacterium avium complex
(one), grade 4 hypersensitivity reaction despite premedication with
dexamethasone (one) and grade 3 oedema with pleural effusion
after six treatment cycles (one). All three patients recovered after
receiving recommended medical treatment. There were no
treatment-related deaths.
DISCUSSION
At initial diagnosis, only a small percentage of endometrial cancer
patients have recurrent or advanced disease with distant
metastases, and therefore a multicentre trial is essential for the
accrual of patients. This multicentre phase II trial, although
relatively small in sample size, clearly demonstrated that docetaxel
is active in the treatment of endometrial cancer. Toxicity was
manageable and predominantly haematologic.
Taxanes have shown activity in this setting previously, with
paclitaxel demonstrating overall response rates of 27–37% when
used as a single agent in endometrial cancer (Ball et al, 1996;
Lissoni et al, 1996; Lincoln et al, 2003). Combination chemo-
therapy with paclitaxel and carboplatin or cisplatin has resulted in
response rates of 50–56% (Dimopoulos et al, 2000; Hoskins et al,
Table 1 Patient characteristics
Characteristic No. of patients (n¼33)
Age, years
Median 59
Range 39–74
ECOG performance status
02 3
19
21
Disease status
Stage III, IV 9
Recurrent 24
Histology
Endometrioid 26
Adenocarcinoma with squamous differentiated 3
Papillary serous 2
Adenocarcinoma, unspecified 1
Undifferentiated 1
Tumour grade
11 1
21 1
36
Unknown 5
Prior treatment
Surgery 29
Radiotherapy 9
Hormonal therapy 5
Prior chemotherapy
None 19
Doxorubicin and platinum 9
Platinum alone 3
Others 2
ECOG¼Eastern Cooperative Oncology Group.
Table 2 Best response (RECIST criteria ) to docetaxel
Prior chemotherapy (n¼13) No prior chemotherapy (n¼19) Total (n¼32)
Response No. of patients % No. of patients % No. of patients %
Complete response 0 0 1 5 1 3
Partial response 3 23 6 32 9 28
Stable disease 4 31 5 26 9 28
Progressive disease 5 38 6 32 11 34
Not assessable 1 8 1 5 2 6
ORR (95% CI) 23 (5.0–53.8) 37 (16.3–61.6) 31 (16.1–50.0)
ORR¼overall response rate; CI¼confidence interval.
0 90 180 270 360 450 540 630 720 810
Time (days)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Medium TTP with confidence intervals:
116.5 days (95% CI, 45.0–305.0 days)
Figure 1 KM curve of estimated TTP.
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s2001; Scudder et al, 2005). However, a GOG randomised trial of
women with advanced or recurrent endometrial carcinoma, in
which the combination paclitaxel doxorubicin was compared
with doxorubicin cisplatin, showed that the paclitaxel arm did
not result in an improved outcome (Fleming et al, 2000). A
subsequent GOG study, in which the combination paclitaxel,
doxorubicin and cisplatin (TAP) with G-CSF was compared with
doxorubicin cisplatin, showed that the TAP arm yielded a better
response (57 vs 34%; Po0.01), progression-free survival (median,
8.3 vs 5.3 months; Po0.01) and OS (median, 15.3 vs 12.3 months;
P¼0.037) than the control arm. However, more grade 3
neuropathy (12 vs 1%) and congestive heart failure were observed
with TAP than with doxorubicin cisplatin (Fleming et al, 2004).
In light of this imbalance between efficacy and toxicity, TAP has
not been accepted as the standard chemotherapy regimen in
routine clinical practice.
Docetaxel has a toxicity profile that is different from paclitaxel.
In particular, neurotoxicity occurs at a low incidence with
docetaxel. In our study, only one patient developed grade 3
neuropathy-sensory and recovered in several weeks. While fluid
retention is a distinctive toxicity of docetaxel, this can be
prevented using premedication (Piccart et al, 1997); in our trial,
one patient developed pleural effusion since the routine pre-
medication with corticosteroids was not applied.
Several studies have reported on second-line chemotherapy for
endometrial cancer. Two phase II trials of second-line paclitaxel
report response rates of 27% (12 out of 44) and 37% (7 out of 19)
(Lissoni et al, 1996; Lincoln et al, 2003). An older report describes
a 30% response rate to second-line high-dose cisplatin (3mgkg
 1)
among 13 patients (Deppe et al, 1980). With the exception of these
studies, response rates to second-line chemotherapy are uniformly
less than 20% and most are less than 10% (Slayton et al, 1982,
1988; Stehman et al, 1983; Thigpen et al, 1984b, 1986; Homesley
et al, 1986; Asbury et al, 1990; Muss et al, 1991, 1993; Sutton et al,
1994; Rose et al, 1996; Muggia et al, 2002). In our study, 23% of
pretreated patients (3 out of 13) had a PR to docetaxel, suggesting
that it too is active as second-line therapy.
In conclusion, this multicentre phase II trial shows that
docetaxel is active in the treatment of chemotherapy-naı ¨ve and
chemotherapy pretreated patients with advanced or recurrent
endometrial cancer and possesses a manageable toxicity profile;
however, the effect was transient and accompanied by pronounced
neutropenia in most patients. The exploration of the efficacy of
docetaxel combinations in phase III studies for the treatment of
endometrial cancer is of great interest and will be initiated.
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